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A retrospective analysis was carried out to identify risk factors for survival and relapse in patients with FIGO stage I–IIB cervical
adenocarcinoma (AC), who underwent radical hysterectomy, and to compare outcome and spread pattern with those of squamous
cell carcinoma (SCC). One hundred and twenty-three FIGO stage I–IIB patients with AC and 455 patients with SCC, who all
underwent primary radical hysterectomy, were reviewed. Among the patients with AC, Cox model identified tumour size (95% CI:
1.35–30.71) and node metastasis (95% CI: 5.09–53.44) as independent prognostic factors for survival, and infiltration to vagina
(95% CI: 1.15–5.76) and node metastasis (95% CI: 6.39–58.87) as independent prognostic factors for relapse. No significant
difference was found in survival or relapse between the AC and SCC groups, after adjusting for other clinicopathological
characteristics using Cox model. No significant difference was found in the positive rates of lymph nodes or location of initial failure
sites between the two groups, but ovarian metastatic rate was significantly higher in patients with pathologic stage IIB AC (P¼0.02).
Positive node is a common independent prognostic factor for survival and relapse of patients with AC. FIGO stage I–IIB patients with
AC or SCC, who underwent radical hysterectomy, have similar prognosis and spread pattern, but different ovarian metastasis rates.
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At present, standard treatment options for patients with invasive
carcinoma of the uterine cervix are as follows: radical hysterec-
tomy followed by adjuvant radiotherapy or primary radiotherapy
with concurrent cisplatin-containing chemotherapy, for the
patients with the International Federation of Gynecology and
Obstetrics (FIGO) stage IB–IIA disease, with equivalent results;
and primary radiotherapy with concurrent chemotherapy for the
patients with FIGO stage IIB–IVA disease. These therapeutic
strategies have been widely accepted. On the other hand,
approximately 85% of the patients with carcinoma of the uterine
cervix have squamous lesions, and most of the remaining 10%
have adenocarcinoma (AC) lesions (Benedet et al, 2003). To our
knowledge, no practice guideline has referred to the treatment
option based on the difference of histological types between AC
and squamous cell carcinoma (SCC) It is not clear whether these
histological types influence outcome or spread pattern, and there
is still controversy, as conflicting results have appeared in the
literature because of potential limitations of small cohorts of
patients with AC. The question whether standard treatment for
patients with SCC is also suitable for patients with AC remains
unanswered. Additionally, over the last decade, the proportion of
AC relative to SCC has doubled, and the rate of AC per population
at risk has also increased (Smith et al, 2000). To establish a
framework for designing therapeutic strategies, the present
retrospective study was undertaken firstly to clarify the clinico-
pathological features of the surgically treated patients with common
type of AC and to identify prognostic factors. Secondly, compa-
risons of outcomes and spread pattern were made between patients
with AC and SCC. Our study will support the design of therapeutic
strategies, including surgery, radiotherapy, and chemotherapy, that
will be more suitable for different disease types.
PATIENTS AND METHODS
Patients
We reviewed the medical records and pathological materials that
had been obtained from 1189 patients with the FIGO stage IB–IVA
invasive carcinoma of the uterine cervix, who were treated at the
Gynecology Division of the National Cancer Center Hospital,
Tokyo, Japan, between 1984 and 2003. This study included patients
who met the following criteria: the patients had (a) common
histological subtypes of endometrioid AC and endocervical type
AC or (b) SCC; the patients had FIGO stage I–IIB disease; and
the patients underwent primary surgery consisting of radical
hysterectomy with pelvic lymphadenectomy. Patients who received
preoperative chemotherapy or radiotherapy were excluded.
Patients with uncommon histological subtypes of AC (adenoma
malignum, villoglandular, intestinal type, clear cell, serous, or
mesonephric AC), and those who had other epithelial carcinoma
(adenosquamous, glassy cell, adenoid cystic, adenoid basal, small
cell, or undifferentiated carcinoma) were also excluded. Patients
with SCC were included in this study for critical comparison of
spread pattern, recurrence, and survival.
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sAll of the patients were staged according to the FIGO staging
system. Postoperative pathological classification was carried
out according to the International Union Against Cancer (UICC)
TNM classification of malignant tumours. Histological typing was
evaluated according to the criteria of the World Health Organiza-
tion International Histological Classification of Tumours.
Treatment
The radicality of hysterectomy in this study corresponded to
classes III and IV of the Piver–Rutledge classification (Piver et al,
1974). In patients with pelvic lymph node metastasis (pT1bN1,
pT2aN1, or pT2bN1) or parametrial involvement (pT2b) proven by
pathological examination following surgery, adjuvant postopera-
tive irradiation to the whole pelvis was administered. A daily dose
of 2Gy, five fractions a week, was given using a linear accelerator.
The total dose for the whole pelvis was 50Gy with an opposed
anterior and posterior field, or a four-field anterior–posterior and
lateral technique. All slides of resected specimens were examined
by three to four pathologists independently, and a consensus
diagnosis was reached. The categories of lymph–vascular space
invasion were defined as follows: after the examination of all
slides of tumour tissues, they were categorised as none (no foci
of lymph–vascular space invasion), few (1–2 foci), several
(3–5 foci), or many (more than 5 foci of lymph–vascular space
invasion).
Following the primary treatment, asymptomatic patients under-
went pelvic examination, Pap smear, chest radiograph, ultrasono-
graphy, and determination of serial tumour markers (SCC, CEA)
every 4–6 months. Symptomatic patients underwent the appro-
priate examination where indicated using computed tomography
(CT) and magnetic resonance imaging (MRI).
Statistical methods
Survival and relapse-free survival (RFS) curves were obtained by
the Kaplan–Meier method and the survival curves were compared
by non-parametric survival analysis (log-rank test). A P-value of
o0.05 was considered to indicate statistical significance. Variables
that showed a significant association with survival were included
in multivariate analysis based on the Cox proportional–hazard
model with a stepwise method (forward selection). A P-value of
o0.05 was adopted as inclusion criteria, and a P-value of 40.10
was adopted as exclusion criteria for the forward selection. For
categorical variables, Fisher’s exact test, or w
2-test was used.
Patients who died of other causes were included as deaths in the
survival analysis. Follow-up continued through to December 2007.
All statistical analyses were carried out with the statistical software




In all, 123 patients with cervical AC and 455 patients with cervical
SCC met the study criteria. The characteristics of the patients are
summarised in Table 1. Median age of the patients with AC was 48
years (range: 29–71) and median age of the patients with SCC was
47 years (range: 22–73). Following surgery, 226 patients received
adjuvant therapy. Majority of the patients received standard
adjuvant therapy, which was irradiation to the whole pelvis, but
five patients with AC who refused radiotherapy received chemo-
therapy. Among the seven patients with positive surgical margin,
five patients received radiotherapy to control microscopic residual
tumour in the vaginal stump, and the remaining two patients
refused postoperative treatment.
All 578 patients were followed for 1–288 months, including until
death, and the median follow-up period was 93 months. The details
with regard to recurrent sites are not available for one patient, who
died of the disease at another hospital.
Survival
The overall survival and the RFS of the patients with AC were
assessed by log-rank test in two clinical and nine pathological
subgroups (Table 2). In these, multivariate analysis testing for
differences in survival among statistically significant subgroups
of FIGO stage, tumour size, depth in cervical wall, number of
positive nodes, degree of lymph–vascular invasion, pathological




No. (%) No. (%) P-value
FIGO stage
IB 96 (78) 275 (60) 0.021
IIA 5 (4) 51 (11)
IIB 22 (18) 129 (29)
Pathological stage
pT1b 88 (72) 229 (50) o0.001
pT2a 14 (11) 112 (25)
pT2b 21 (17) 114 (25)
Tumour size (mm)
%20 37 (30) 92 (20) 0.024
21–40 46 (37) 222 (49)
440 40 (33) 141 (31)
Depth in cervical wall
o1/3 34 (28) 68 (15) 0.002
1/3–2/3 31 (25) 107 (23)
42/3 58 (47) 280 (62)
Number of positive pelvic lymph nodes
None 91 (74) 309 (68) 0.329
1–4 25 (20) 104 (23)
^5 7 (6) 42 (9)
Lymph–vascular space invasion
None 53 (43) 102 (22) o0.001
Few 32 (26) 149 (33)
Several 27 (22) 110 (24)
Many 11 (9) 94 (21)
Infiltration to vagina
No 94 (76) 280 (62) 0.003
Yes 29 (24) 175 (38)
Ovarian metastases
Negative 116 (94) 448 (98.5) 0.024
Positive 6 (5) 6 (1.3)
Not resected 1 (1) 1(0.2)
Surgical margin
Free 121 (98) 450 (99) 0.644
Close or involved 2 (2) 5 (1)
Postoperative therapy
Not carried out 94 (76) 253 (56) o0.001
Radiotherapy 24 (20) 202 (44)
Chemotherapy 5 (4) 0
FIGO¼the International Federation of Gynecology and Obstetrics.
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sparametrial involvement, infiltration to vagina, ovarian metastases,
and histological grade was carried out. The Cox model with a
forward stepwise method identified that tumour size (over
40mm) and number of positive nodes were independent
prognostic factors for overall survival. Similarly, the RFS was also
assessed in the subgroups according to age in addition to the same
parameters as overall survival. The Cox model showed that
infiltration to vagina and number of positive nodes were
independent prognostic factors for relapse (Table 3). Among the
patients who recurred, one patient with pT1b-2N1 disease survived
after recurrence.
Comparison of survival rate was made between the patients with
AC and those with SCC according to UICC pathological stage.
Among the patients with AC, the cumulative 5-year survival rates
of the patients with pathological stage pT1b, pT2a, and pT2b
diseases were 89, 92, and 38%, respectively. Among the patients
with SCC, the 5-year survival rates of the patients with pT1b, pT2a,
and pT2b diseases were 89, 89, and 62%, respectively. Univariate
analysis revealed no significant difference in survival between
patients with AC and SCC (log-rank, P¼0.640 in the patients with
pT1b disease, P¼0.317 in pT2a disease, and P¼0.074 in pT2b
disease). Similarly, among the patients with AC, the RFS rates at 36
months of the patients with pT1b, pT2a, and pT2b diseases were
91, 100, and 38%, respectively, compared with 91, 91, and 61% of
the patients with SCC, respectively. There were no significant
differences in relapse between patients with AC and SCC (log-rank,
P¼0.860 in the patients with pT1b disease, P¼0.227 in pT2a,
and P¼0.137 in pT2b). To adjust for other clinicopathological
characteristics, the Cox model was used for survival and RFS
analyses among the subgroups according to age, postoperative
therapy, tumour size, depth in cervical wall, lymph node status,
LVS invasion, ovarian metastasis, and histological types (AC or
SCC). The Cox model-adjusted clinicopathological characteristics
showed no significant difference in survival or relapse between the
AC and SCC groups (Tables 4 and 5). Histological type was not
shown to be an independent factor of survival or relapse at any
pathological stage.
Spread pattern and failure sites
Among the 123 patients with AC, the positive rate of pelvic lymph
node metastasis at the initial surgery was 16% (14 of 88) of the
patients with pT1b disease, 14% (2 of 14) of the patients with pT2a
disease, and 76% (16 of 21) of the patients with pT2b disease,
compared with 17% (38 of 229), 21% (23 of 112), and 75% (85 of
114), respectively, of the patients with SCC. There were no
significant differences in the positive node rates between AC and
SCC groups (Fisher’s exact test, P¼1.000 in the patients with pT1b
disease, P¼0.735 in the patients with pT2a disease, and P¼1.000
in the patients with pT2b disease). With regard to the paraaortic
lymph node status, in the AC group, no enlarged paraaortic nodes
were found during the operation. Further, common iliac node








(%) (%) P-value (%) P-value
Age
%48 67 (54) 84 0.091 85 0.017
448 56 (46) 77 80
FIGO stage
IB 96 (78) 86 0.004 89 0.001
IIA 5 (4) 53 60
IIB 22 (18) 59 59
Tumour size (mm)
%20 37 (30) 95 o0.001 97 o0.001
21–40 46 (37) 91 91
440 40 (33) 55 59
Depth in cervical wall
o1/3 34 (28) 97 0.004 100 0.001
1/3–2/3 31 (25) 87 87
42/3 58 (47) 67 87
Number of positive nodes
None 91 (74) 91 o0.001 93 o0.001
1–4 25 (20) 60 63
^5 7 (6) 14 14
LVS invasion
b
None 53 (43) 98 o0.001 98 o0.001
Few 32 (26) 81 84
Several 27 (22) 56 61
Many 11 (9) 55 55
Parametrial invasion
Negative 102 (83) 89 o0.001 92 o0.001
Positive 21 (17) 38 43
Infiltration to vagina
No 94 (76) 87 o0.001 89 o0.001
Yes 29 (24) 61 62
Ovarian metastases
Negative 94 (95) 84 o0.001 85 o0.001
Positive 6 (5) 17 20
Histological subtype
Mucinous 73 (59) 75 0.543 78 0.180
Endometrioid 50 (41) 88 90
Histological grade
Grade 1 86 (70) 85 o0.001 86 o0.001
Grade 2 23 (19) 87 86
Grade 3 14 (11) 47 56
FIGO¼the International Federation of Gynecology and Obstetrics; LVS¼lymph–
vascular space; RFS¼relapse-free survival.
aRFS at 36 months.
bLVS invasion.
Table 3 Multivariate analysis of prognostic factors for OS and RFS in 123




b P-value HR 95% CI P-value
Infiltration to vagina
No — — — 1.00
Yes — — — 2.58 1.15–5.76 0.020
Tumour size (mm)
%20 1.00
21–40 2.25 0.45–11.29 0.323 — — —
440 6.44 1.35–30.71 0.019 — — —
Number of positive nodes
None 1.00 1.00
1–4 2.63 1.13–6.10 0.024 3.86 1.58–9.41 0.003
45 16.50 5.09–53.44 o0.001 19.39 6.39–58.87 o0.001
AC¼adenocarcinoma; CI¼confidence interval; FIGO¼the International Federation
of Gynecology and Obstetrics; HR¼hazard ratio; LVS¼lymph–vascular space;
OS¼overall survival; RFS¼relapse-free survival.
aThe analysis was adjusted for FIGO
stage, tumour size, depth in cervical wall, number of positive node, degree of LVS
invasion, pathological parametrial involvement, infiltration to vagina, ovarian
metastases, and histological grade.
b95% confidence interval.
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smetastasis was proven in 10 (31.3%, 10 of 32) patients with positive
pelvic lymph nodes. In the SCC group, 41 (28.1%, 41/146) patients
with positive pelvic lymph nodes had common iliac node
metastasis. Of these, eight patients had paraaortic lymph node
metastasis, which was proven histopathologically, and enlarged
paraaortic lymph nodes were not found during the operation in
the remaining patients.
Among the patients with AC, ovarian metastasis was found
in one patient (1.1%, 1 of 87) with pT1b disease, no patient with
pT2a disease, and five patients (23.8%, 5 of 21) with pT2b disease.
Among the patients with SCC, ovarian metastasis was found in
one patient (0.4%, 1 of 228) with pT1b disease, two patients (1.7%,
2 of 112) with pT2a disease, and three patients (2.6%, 3 of 114)
with pT2b disease. Significant difference was found in ovarian
metastatic rate between AC and SCC groups with pT2b disease
(Fisher’s exact test, P¼0.477 in the patients with pT1b disease,
P¼1.000 in the patients with pT2a disease, and P¼0.002 in the
patients with pT2b disease). From the viewpoint of clinical FIGO
stage, the ovarian metastatic rates in the AC group were 3.2% (3 of
95) of patients with FIGO stage IB, 0% (0 of 5) with FIGO stage IIA,
and 13.6% (3 of 22) with FIGO stage IIB. Similarly, in the SCC
group, the ovarian metastatic rates were 0.4% (1 of 274) of patients
with FIGO stage IB, 1.9% (1 of 51) with FIGO stage IIA, and 3.1%
(4 of 129) with FIGO stage IIB.
Among the 123 patients with AC, 27 patients (22%) suffered
tumour recurrence. Of these, the initial failure sites were located
inside the pelvis in 10 (38%) patients, outside the pelvis in 15
(58%) patients, and both inside and outside the pelvis in 1 (4%)
patient. Unknown site was in one patient. Among the 455 patients
with SCC, 89 (20%) patients suffered recurrence. The initial failure
sites were located inside the pelvis in 28 (32%) patients, outside the
pelvis in 57 (64%) patients, and both inside and outside the pelvis
in 4 (4%) patients. No significant difference was found in location
of initial failure sites between AC and SCC groups (w
2-test,
P¼0.288).
Of all initial failure sites located outside the pelvis in the 15
patients with AC who recurred, the most frequent sites were
distant nodes (48%) and peritoneal spread (48%), followed by the
lung (8%) and bone (8%). In the 57 patients with SCC, the most
frequent sites located outside the pelvis were distant nodes (48%),
followed by the lung (25%), bone (16%), the liver (9%), and
peritoneal spread (2%).
Table 4 Multivariate analysis of prognostic factors for OS in 123 patients
with AC and 455 patients with SCC (with a stepwise method, forward
selection)
PT1b pT2a pT2b






Carried out P40.10 P40.10 1.00
Not carried out 2.44 1.38–4.32
Tumour size (mm)
%20 1.00 P40.10 P40.10
21–40 2.37 0.95–5.90
440 4.00 1.48–10.75
Number of positive nodes
None 1.00 1.00 1.00
1–4 1.71 0.80–3.68 1.99 0.54–7.29 1.66 0.88–3.16
45 7.76 2.70–22.27 46.38 3.26–658.60 5.25 2.65–10.39
Ovarian metastases
Negative P40.10 P40.10 1.00
Positive 2.66 1.00–7.04
Depth in cervical wall









SCC P40.10 P40.10 P40.10
AC
AC¼adenocarcinoma; CI¼confidence interval; FIGO¼the International Federation
of Gynecology and Obstetrics; HR¼hazard ratio; LVS¼lymph–vascular space;
OS¼overall survival; SCC¼squamous cell carcinoma.
aP40.10 was exclusion
criteria for the stepwise, forward selection.
Table 5 Multivariate analysis of prognostic factors for RFS in 123 patients
with AC and 455 patients with SCC (with a stepwise method, forward
selection)
pT1b pT2a pT2b






Done P40.10 P40.10 1.00
Not done 3.14 1.75–5.64
Tumour size (mm)
%20 1.00 P40.10 P40.10
21–40 2.63 0.87–7.94
440 7.25 2.34–22.48
Number of positive nodes
None 1.00 1.00 1.00
1–4 1.75 0.79–3.86 3.63 1.15–11.47 2.04 0.93–4.93
45 8.30 2.83–24.33 13.85 2.83–67.68 6.62 3.00–14.64
Ovarian metastases
Negative P40.10 P40.10 P40.10
Positive
Depth in cervical wall









SCC P40.10 P40.10 P40.10
AC
AC¼adenocarcinoma; CI¼confidence interval; FIGO¼the International Federation
of Gynecology and Obstetrics; HR¼hazard ratio; LVS¼lymph–vascular space;
OS¼overall survival; RFS¼relapse-free survival; SCC¼squamous cell carcinoma.
aP40.10 was exclusion criteria for the stepwise, forward selection.
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Since 1980, three studies using multivariate analysis have reported
prognostic factors in patients with cervical AC who underwent
radical hysterectomy followed by adjuvant radiotherapy.
Matthews et al (1993) showed that only nodal positivity was the
major prognostic factor for survival in 79 patients with clinical
stage I disease. Irie et al (2000) also reported the same result in
57 patients with FIGO stage I–IIB disease (Irie et al, 2000).
Ishikawa et al (1999) reported that the clinical stage, the presence
of nodal metastasis, lymph–vascular space invasion, and tumour
size were independent risk factors in 193 patients with FIGO stage
I–IV disease, and number of positive nodes and tumour size were
independent risk factors in survival and relapse among patients
with FIGO stage I disease. These results were dependent on
characteristics of the enrolled patients because of their small
cohorts. These three reports included several pathological subtypes
of adenosquamous cell carcinoma, clear cell carcinoma, or
subtypes of which details were not mentioned. As for the
prognostic significance of pathological subtype, conflicting results
have appeared in the literature (Korhonen, 1984; Alfsen et al,
2001; Lea et al, 2003). In this study, we employed only ordinary
subtypes of AC of the uterine cervix to simplify the analysis.
Nonetheless, based on the literature and our data, it is reasonably
certain that nodal positivity is recognised as a common
independent adverse prognostic factor for survival and relapse
of the patient with FIGO stage I–IIB disease who underwent
radical hysterectomy. Tumour size was an independent adverse
factor only for survival, and vaginal infiltration was an inde-
pendent risk factor only for relapse. The following is our
explanation regarding these issues. In contrast to SCC, cervical
AC arises from the endocervix. The lesion expands into the
endocervix and characteristically creates a bulky tumour in the
cervical canal, after which it invades the vagina directly. In this
study, 66% (19 of 29) of the patients in the AC group with vaginal
infiltration had large-sized tumours (440mm), compared with
42% (74 of 175) in the SCC group. There may be multicollinearity
between tumour size and vaginal invasion as assessed by the
Cox model.
In this study, there was no significant difference in
survival or relapse, after adjusting for other clinicopathological
characteristics, between the AC and SCC groups at any patho-
logical stage. One limitation of this study was that it was a
retrospective study with a limited number of statistical events,
thus, it was difficult to evaluate power calculation statistically.
Grisaru et al (2001) reported that 799 surgically treated patients
with FIGO stage IA–IB disease of AC or SCC had a similar
prognosis. Look et al (1996) and Lee et al (2006) reported same
results in 749 and 60 patients with FIGO stage IB disease,
respectively. A similar finding was noted in a study from
Fregnani et al (2008), in which 238 FIGO stage IB–IIA patients
with AC or SCC were assessed. In these reports, radical
hysterectomy followed by adjuvant radiotherapy was employed
as a treatment modality. Nakanishi et al (2000) showed that
histology of AC was an independent significant risk factor
for survival and relapse in pathologic stage IB (pT1b) patients
who underwent radical hysterectomy. They also reported that
the prognosis of patients with AC was poorer than that of
patients with SCC in the presence of lymph node metastasis,
whereas the prognosis was equivalent when there was no meta-
stasis. Although further investigation is still needed, considering
our data and the present literature, radical hysterectomy followed
by adjuvant radiotherapy is still considered the standard treat-
ment option for early stage cervical AC with equivalent results
for cervical SCC. However, there is still controversy regarding
the advanced stage disease, that is, FIGO stage IIB. Radiotherapy
has been employed as the standard treatment option for FIGO
stage IIB disease in many countries, and radical hysterectomy
has been adopted for stage IB–IIA disease (Suprasert et al,
2005). The 25th FIGO annual report from 93 centres throughout
the world reported that 72% (2320 of 3233) of the patients
with stage IIB disease were treated with radiotherapy (Benedet
et al, 2003). Accordingly, few reports discuss the radical
hysterectomy for patients with FIGO stage IIB cervical AC. On
the other hand, it was noted that although primary radiotherapy
is effective for patients with small volume stage IB AC lesions
with equivalent results for SCC lesions, it does not appear to be
sufficient for patients with advanced stage II or large tumour
size AC lesions (Eifel et al, 1990, 1995; Berek, 1995). This study
included the patients with stage IIB disease who also under-
went radical hysterectomy. In our institute, 88% of the patients
with stage IIB AC underwent radical hysterectomy of classes III
and IV, and the remaining 12% were treated by primary
radiotherapy during the study period. Consequently, no significant
difference was found in survival or relapse between the surgically
treated patients with pT2b AC and SCC lesions in this study.
Considering the above facts, radical hysterectomy may be a
treatment of choice for stage IIB disease in cases of AC in contrast
to SCC.
The incidence of ovarian metastasis of AC lesion was
significantly higher than that of SCC of pT2b lesion in this
study. Similarly, Nakanishi et al (2001) reported that the
incidences of metastasis of FIGO stages IB and IIB AC lesions
were 4.0 (7 of 178) and 14.8% (4 of 27), respectively, whereas the
incidences of FIGO stages IB and IIB SCC lesions were 0.5 (3 of
614) and 4.0% (7 of 175), respectively. When pathological
parametrial invasion was present, the incidence increased from
3 to 25.6%. In their report, using a logistic analysis with
clinicopathological variables revealed that the presence of
pathological endometrial invasion, lymph node metastasis, and
pathological parametrial invasion were the significant variables
associated with ovarian metastasis of AC lesion. Ovarian
preservation should not be recommended in cases of AC except
for very early lesions.
In this study, there were no significant differences in positive
rates of pelvic lymph node between AC and SCC groups at
any pathological stage. In the reported literature, no differences
were found in positive lymph node rates of FIGO stage IB
disease, and positive rates were approximately 5–15% (Look et al,
1996; Irie et al, 2000; Lee et al, 2006). Few reported literature
have discussed lymph node status of advanced stage, that is,
FIGO stage IIB. Irie et al (2000) reported a higher positive rate of
lymph node in patients with AC than in those with SCC of FIGO
stage II disease (57.1 vs 26.9%). This discrepancy is probably
because of the number of patients, the difference in histological
subtypes of AC, and/or the difference between clinical and
pathological stages.
No differences were noted in initial failure sites among
the patients in the two histological groups, which were classified
into inside and outside the pelvis in this study. A similar finding
was reported in a study by Grisaru et al (2001), in which 100
patients with FIGO stage IA–IB disease were treated in the same
manner. Of the distribution of the distant metastatic sites,
peritoneal spread was more frequent in AC (48 vs 2%) in our
study. Drescher et al (1989) reported that disseminated peritoneal
involvement was twice as frequent in patients with AC from 21
autopsy findings. Although the data are not yet sufficient,
disseminated peritoneal spread might be a characteristic of AC
of the uterine cervix.
In conclusion, number of positive nodes is a common
independent prognostic factor for survival and relapse among
the FIGO stage I–IIB patients with ordinary types of AC who
underwent radical hysterectomy followed by adjuvant radio-
therapy. Surgically treated patients with AC or SCC have a
similar prognosis and spread pattern, but not the ovarian
metastasis rate.
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